.png)
What is the Genentech patient Foundation?
Genentech Patient Foundation Living with a serious illness can come with many challenges. Getting Genentech medicines shouldn’t be one of them. The Genentech Patient Foundation gives free Genentech medicine to people who don’t have insurance coverage or who have financial concerns.
What is Genentech access solutions?
Genentech Access Solutions: A team at Genentech that works with your doctor and health insurance plan to help you get your medicine. Genentech Patient Foundation: A program that gives free Genentech medicine to people who don't have insurance coverage or who have financial concerns and meet certain eligibility criteria.
Can you get Genentech medicines for free?
Getting Genentech medicines shouldn’t be one of them. The Genentech Patient Foundation gives free Genentech medicine to people who don’t have insurance coverage or who have financial concerns. See if You Qualify Find out if the Genentech Patient Foundation can help you.
What is Genentech doing for patients with AIS?
At Genentech, we are dedicated to supporting healthcare providers and their institutions in delivering quality care to patients. The following resources were developed to help healthcare professionals with treating patients with AIS and the appropriate use of Activase®. Filter by Activase for Acute Ischemic Stroke Show All
See more
How to contact Genentech about activase?from gene.com
SUPPORT. Medicine Information Support. Medical information about Genentech medicines. Call us at (800) 821-8590, Monday-Friday, 5am-5pm PT. Request a Call Back. Request an Office Visit with a Medical Science Liaison.
What is Genentech dedicated to?from genentechmaterials.com
At Genentech, we are dedicated to supporting healthcare providers and their institutions in delivering quality care to patients. The following resources were developed to provide disease education resources to help in diagnosing and assessing stroke.
What are the risks of activase?from activase.com
In the following conditions, the risks of bleeding with Activase are increased and should be weighed against the anticipated benefits: recent major surgery or procedure; cerebrovascular disease; recent intracranial hemorrhage; recent gastrointestinal or genitourinary bleeding; recent trauma; hypertension; acute pericarditis; subacute bacterial endocarditis; hemostatic defects including those secondary to severe hepatic or renal disease; significant hepatic dysfunction; pregnancy; diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions; septic thrombophlebitis or occluded AV cannula at seriously infected site; advanced age; and patients currently receiving oral anticoagulants, or any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location.
What is activase resource center?from genentechmaterials.com
Activase Resource Center: Supporting you in the treatment of acute ischemic stroke (AIS) patients
What is BFCR4350A?from gene.com
Cevostamab (BFCR4350A, RG6160) is a T-cell engaging bispecific antibody designed to target FcRH5 on myeloma cells and CD3 on T-cells. This dual targeting is designed to activate and redirect T-cells to attack FcRH5-expressing myeloma cells.
What is the most common adverse reaction associated with activase therapy?from activase.com
The most frequent adverse reaction associated with Activase therapy is bleeding.
How soon after stroke can you start activase?from activase.com
Initiate treatment as soon as possible but within 3 hours after symptom onset. Activase is indicated for use in acute myocardial infarction (AMI) for the reduction of mortality and reduction of the incidence of heart failure.
What is activase used for?
Activase is indicated for use in acute myocardial infarction (AMI) for the reduction of mortality and reduction of the incidence of heart failure. Limitation of Use: The risk of stroke may outweigh the benefit produced by thrombolytic therapy in patients whose AMI puts them at low risk for death or heart failure.
What is the most common adverse reaction associated with activase therapy?
The most frequent adverse reaction associated with Activase therapy is bleeding.
What are the risks of activase?
In the following conditions, the risks of bleeding with Activase are increased and should be weighed against the anticipated benefits: recent major surgery or procedure; cerebrovascular disease; recent intracranial hemorrhage; recent gastrointestinal or genitourinary bleeding; recent trauma; hypertension; acute pericarditis; subacute bacterial endocarditis; hemostatic defects including those secondary to severe hepatic or renal disease; significant hepatic dysfunction; pregnancy; diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions; septic thrombophlebitis or occluded AV cannula at seriously infected site; advanced age; and patients currently receiving oral anticoagulants, or any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location.
Can activase cause bleeding?
Activase can cause significant, sometimes fatal internal or external bleeding, especially at arterial and venous puncture sites. Avoid intramuscular injections and trauma to the patient. Perform venipunctures carefully and only as required. Fatal cases of hemorrhage associated with traumatic intubation in patients administered Activase have been reported. Aspirin and heparin have been administered concomitantly with and following infusion with Activase in the management of acute myocardial infarction and pulmonary embolism. The concomitant administration of heparin and aspirin with and following infusions of Activase for the treatment of acute ischemic stroke during the first 24 hours after symptom onset has not been investigated. Because heparin, aspirin, or Activase may cause bleeding complications, carefully monitor for bleeding, especially at arterial puncture sites. Hemorrhage can occur 1 or more days after administration of Activase, while patients are still receiving anticoagulant therapy. If serious bleeding occurs, terminate the Activase infusion, and treat appropriately.
Can activase be used for pulmonary embolism?
Do not administer Activase to treat acute myocardial infarction or pulmonary embolism in the following situations in which the risk of bleeding is greater than the potential benefit: active internal bleeding; history of recent stroke; recent (within 3 months) intracranial or intraspinal surgery or serious head trauma; presence of intracranial conditions that may increase the risk of bleeding; bleeding diathesis; and current severe uncontrolled hypertension.
Can activase be used for ischemic stroke?
Do not administer Activase to treat acute ischemic stroke in the following situations in which the risk of bleeding is greater than the potential benefit: current intracranial hemorrhage (ICH); subarachnoid hemorrhage; active internal bleeding; recent (within 3 months) intracranial or intraspinal surgery or serious head trauma; presence of intracranial conditions that may increase the risk of bleeding (e.g., some neoplasms, arteriovenous malformations, or aneurysms); bleeding diathesis; and current severe uncontrolled hypertension.
Does activase help with thromboembolism?
Thromboembolism. The use of thrombolytics can increase the risk of thrombo-embolic events in patients with high likelihood of left heart thrombus, such as patients with mitral stenosis or atrial fibrillation. Activase has not been shown to treat adequately underlying deep vein thrombosis in patients with PE.
Important Note
The following information is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that use of the drug is safe, appropriate, or effective for you. Consult your healthcare professional before using this drug.
Uses
This medication is an enzyme which works to break up and dissolve blood clots which can block arteries. It is used in the treatment of an acute heart attack or pulmonary embolism.
How To Use
This medication is given by injection within 6 hours of chest pain by a health care professional. It is usually given over a two to three hour period. Continued or repeated doses are not usually required. It is important this medication be used as prescribed.
Side Effects
Nausea, vomiting, dizziness or mild fever may occur. If any of these effects continue or become bothersome, inform your doctor. Notify your doctor if you experience: easy bruising or bleeding, skin rash, trouble breathing, rapid or abnormal heartbeat, chest pain. Immediately report any signs of bleeding to your doctor.
Drug Interactions
Tell your doctor of any over-the-counter or prescription medication you may take including: "blood thinners" (e.g., warfarin), aspirin. Do not start or stop any medicine without doctor or pharmacist approval.
Overdose
If overdose is suspected, contact your local poison control center or emergency room immediately. Symptoms of overdose may include fainting, vision changes, one-sided weakness, slurred speech, black stools, coughing up or vomiting blood, dizziness upon standing.
Notes
Laboratory tests will be done frequently while using this medication to monitor its effects and to prevent side effects.
What is Genentech dedicated to?
At Genentech, we are dedicated to supporting healthcare providers and their institutions in delivering quality care to patients. The following resources were developed to provide disease education resources to help in diagnosing and assessing stroke.
What is activase resource center?
Activase Resource Center: Supporting you in the treatment of acute ischemic stroke (AIS) patients
What are the risks of activase?
In the following conditions, the risks of bleeding with Activase are increased and should be weighed against the anticipated benefits: recent major surgery or procedure; cerebrovascular disease; recent intracranial hemorrhage; recent gastrointestinal or genitourinary bleeding; recent trauma; hypertension; acute pericarditis; subacute bacterial endocarditis; hemostatic defects including those secondary to severe hepatic or renal disease; significant hepatic dysfunction; pregnancy; diabetic hemorrhagic retinopathy or other hemorrhagic ophthalmic conditions; septic thrombophlebitis or occluded AV cannula at seriously infected site; advanced age; and patients currently receiving oral anticoagulants, or any other condition in which bleeding constitutes a significant hazard or would be particularly difficult to manage because of its location.
What is the most common adverse reaction associated with activase therapy?
The most frequent adverse reaction associated with Activase therapy is bleeding.
How soon after stroke can you start activase?
Initiate treatment as soon as possible but within 3 hours after symptom onset. Activase is indicated for use in acute myocardial infarction (AMI) for the reduction of mortality and reduction of the incidence of heart failure.
How many mg of activase is in a vial?
Video: Dosing and Administration With Activase® (alteplase) 50-mg vials
Can activase cause anaphylactic reactions?
Hypersensitivity, including urticarial / anaphylactic reactions, have been reported after administration of Activase. Rare fatal outcome for hypersensitivity was reported. Angioedema has been observed during and up to 2 hours after Activase infusion in patients treated for acute ischemic stroke and acute myocardial infarction. In many cases, patients received concomitant angiotensin-converting enzyme inhibitors. Monitor patients treated with Activase during and for several hours after infusion for hypersensitivity. If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine).
Prescriber Service Form
The Prescriber Service Form includes patient, insurance and prescription information used when Genentech Access Solutions contacts a patient’s health insurance plan to determine his or her coverage.
Patient Consent Form
This form is signed and dated by your patient giving written permission for Genentech Access Solutions to discuss his or her health information with you and the patient’s health insurance plan.
Formulario de Consentimiento del Paciente
A version of the Patient Consent Form for your Spanish-speaking patients.
Other Important Documents
The Genentech Patient Foundation gives free Genentech medicine to people who don't have insurance or who have financial concerns and meet eligibility criteria. Two forms are needed to enroll in the Genentech Patient Foundation:
Summary
Genentech, Inc. was founded in 1976 by Robert A. Swanson and Dr. Herbert W. Boyer. The company is primarily based around the field of recombinant DNA technology that was founded by Boyer and colleague Stanley Cohen. Over their 30+ year history, Genentech, Inc.
Eligibility
Genentech Access To Care Foundation (Avastin, Herceptin, Rituxan), a patient assistance program provided by Genentech, Inc., offers the medications listed to the right at no cost to those who are eligible for the program. Eligibility is based off of the following requirements:
Other Tips
If you have any questions please call the Genentech, Inc. program directly.
